Partial
Partially Aligned
Patient Risk:
Low
Summary
The label supports the identification of rivaroxaban as XARELTO’s active ingredient and the claims that dosing varies by indication and renal function. It does not address generic naming, availability, country-specific product names, or patent and exclusivity effects. The label also does not establish that other anticoagulants are therapeutic alternatives or that matching ingredient, strength, and schedule establishes interchangeability.
Category Scores
Accurate Statements
Xarelto is the brand name for rivaroxaban.
Section 11 identifies rivaroxaban as the active ingredient in XARELTO.
Rivaroxaban dosing depends on the condition being treated and kidney function.
Section 2.1 provides indication-specific dosages and renal considerations; Section 5.4 discusses renal-function assessment and therapy adjustments.
Rivaroxaban dosing schedules may differ for stroke prevention in atrial fibrillation, DVT or PE treatment, and VTE prevention after surgery.
Section 2.1 provides different dosage schedules for these indications.
When replacing Xarelto, the alternative should have the same active ingredient, tablet strength, and dose schedule appropriate for the indication.
The label identifies rivaroxaban as XARELTO’s active ingredient, lists tablet strengths, and provides indication-specific dosing. It does not recommend this as a replacement rule or establish interchangeability.
Other anticoagulants may be alternatives to Xarelto if a clinician determines that switching is appropriate.
Section 2.3 provides instructions for transitioning between XARELTO and other anticoagulants, but does not characterize them as therapeutic alternatives.
Unsupported Statements
Generic rivaroxaban products are labeled with the generic name rather than the brand name Xarelto.
The supplied label does not discuss generic products or their labeling.
Rivaroxaban products may be approved under different brand or generic names depending on the country and strength.
The supplied label does not discuss country-specific approvals or other product names.
Generic rivaroxaban availability varies by market.
The supplied label does not address generic availability or market variation.
In the United States, generic alternatives to Xarelto are typically labeled as rivaroxaban when regulatory approvals and exclusivities allow.
The supplied label does not discuss U.S. generic alternatives, regulatory approvals, or exclusivities.
When replacing Xarelto, the alternative should have the same active ingredient, tablet strength, and dose schedule appropriate for the indication.
The label supports the ingredient, available strengths, and dosing information, but does not advise that these features establish that a replacement product is interchangeable.
Other anticoagulants may be alternatives to Xarelto if a clinician determines that switching is appropriate.
Transition instructions in Section 2.3 do not establish that other anticoagulants are therapeutic alternatives or support the stated recommendation.
Patent and regulatory exclusivity status can affect when generic rivaroxaban can launch.
The supplied label does not discuss patents, exclusivity, or generic launch timing.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims do not provide a specific dosing instruction or direct the reader to switch products. However, the label does not establish generic interchangeability or characterize other anticoagulants as alternatives.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims about generic naming, availability, market variation, and patent or exclusivity effects are not addressed by the supplied label; switching claims go beyond its transition instructions.
Suggested Improvement
Separate label-supported information from claims about generic products and market status, and avoid implying that matching ingredient, strength, and schedule establishes interchangeability.